Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
about
IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.Secukinumab in the treatment of psoriasis: an update."Inflammatory skin march" in atopic dermatitis and psoriasis.Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Pustular psoriasis and related pustular skin diseases.Autoimmunity and autoimmune co-morbidities in psoriasis.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.Rare diseases and costly treatments: the role of IL-1β in pustular psoriasis.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Secukinumab in the treatment of psoriasis: patient selection and perspectivesRecalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
P2860
Q38438511-16E99A8D-9566-4300-9C67-B249EFAAD3B6Q38764424-C71A2ACA-5DE2-417F-AAC1-DF511CD7F7AFQ39120166-35F90B06-538A-4128-ACBF-190E56ABD135Q39377564-0EF10ACE-254F-44BA-B82C-698897C0146FQ39412708-F858819C-CE25-4189-8F1A-749EF0E6E81CQ47342126-3763E99A-AB00-45FD-A140-765F2D4FF825Q47727612-ED7BA217-6C63-4A98-8A20-4BF128A09030Q48170767-E3E4963E-6F29-4DE0-91E4-9CD6D8B8EB0BQ48245430-E83E7E54-524F-45AB-A5A5-298CE4360C69Q48283379-84B7A763-C8C4-4EB3-AE27-FA92DAE069A3Q49985388-9E292DAD-FDCA-4B54-B3FA-F63CC4A60B61Q51184652-C8E5A811-42D2-47A8-9CCF-140B001B2AFCQ53835593-85A2051D-8C93-4E51-B115-97CF89BBA978Q58694680-864834B1-1118-4E5B-9F74-3D5ABD241503Q58718984-747BF0B6-4A87-4AD2-9601-654E64E7A514
P2860
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy and safety of secukin ...... el multicenter Japanese study.
@en
Efficacy and safety of secukin ...... el multicenter Japanese study.
@nl
type
label
Efficacy and safety of secukin ...... el multicenter Japanese study.
@en
Efficacy and safety of secukin ...... el multicenter Japanese study.
@nl
prefLabel
Efficacy and safety of secukin ...... el multicenter Japanese study.
@en
Efficacy and safety of secukin ...... el multicenter Japanese study.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of secukin ...... bel multicenter Japanese study
@en
P2093
Akimichi Morita
Hidemi Nakagawa
Mamitaro Ohtsuki
Masaru Honma
Naoko Kawashima
Noriko Seko
Shinichi Imafuku
Tomohiro Shima
Yukari Okubo
P2860
P304
P356
10.1111/1346-8138.13306
P577
2016-02-26T00:00:00Z